LabyRx has developed unconventional cancer therapeutics directed against a novel cancer target.  Our unique target is called Labyrinthin*. 

Our lead product, LabVax, is a Labyrinthin-derived synthetic peptide vaccine that recruits the body's immune cells to attack adenocarcinomas cancers,  which represent approximately 40% of all cancers and over 60% of all cancer deaths.